Key Stats for AbbVie Stock
- 52-Week Range: $177 to $245
- Current Price: $201
- Street Mean Target: $249
- Street High Target: $294
- Analyst Consensus: 15 Buys, 8 Outperforms, 9 Holds, 1 No Opinion
- TIKR Model Target (Dec. 2030): $319
What Happened?
AbbVie Inc. (ABBV), a global biopharmaceutical company whose growth was once tethered to a single blockbuster drug, is now generating record revenues as two next-generation immunology medicines replace and surpass what Humira delivered at its commercial peak.
The clearest proof of that transition: Skyrizi (risankizumab) and Rinvoq (upadacitinib) — two immunology treatments for psoriasis, inflammatory bowel disease, and rheumatoid arthritis — delivered a combined $25.9 billion in revenue in 2025, more than $8 billion above the prior year, already exceeding AbbVie’s own 2027 long-term peak guidance by more than $500 million.
That growth rate is not decelerating; in Q4 alone, Skyrizi posted operational growth of 31.9% and Rinvoq grew 28.6%, with AbbVie guiding the combined franchise to over $31 billion in 2026, representing more than 20% growth on an already enormous base.
AbbVie CEO Robert Michael stated on the Q4 2025 earnings call that “Skyrizi and Rinvoq are a great pair in IBD — Skyrizi is well positioned in frontline, and we see more opportunity than ever before for Rinvoq in the second-line plus setting,” capturing a portfolio architecture that competitors anchored to a single asset cannot easily replicate.
AbbVie is simultaneously deploying capital at a pace that extends the runway well into the next decade: the company announced a $1.4 billion manufacturing campus in Durham, North Carolina in April, committed more than $100 billion in U.S. R&D and manufacturing investment over ten years, and is progressing Phase III programs for lutikizumab in hidradenitis suppurativa (a chronic skin condition with fewer than 5% of eligible patients currently on biologic therapy), etentamig in multiple myeloma, and the Parkinson’s drug tavapadon targeted for U.S. approval in Q3 2026.
The FDA’s issuance of a complete response letter for TrenibotE — an experimental short-acting botulinum toxin for facial wrinkles — on manufacturing grounds represented a setback for AbbVie’s aesthetics pipeline, though the agency raised no safety or efficacy concerns and management expects to resubmit within months, with a revised approval path extending into 2027.
Wall Street’s Take on ABBV Stock
The Humira patent cliff spent three years scaring capital out of AbbVie stock, and the market’s multiple still reflects that fear even as the operational data points the other way.
ABBV’s normalized EPS troughed at $10.00 in 2025, absorbing nearly $16 billion in cumulative U.S. Humira erosion, with consensus now projecting a recovery to around $14 in 2026 and roughly $16 in 2027, driven by the Skyrizi and Rinvoq franchise expanding at 20%-plus on a $26 billion combined base.
Free cash flow guided to approximately $18.5 billion in 2026, up roughly 48% from $17.82 billion in 2025, creates capacity for a dividend that has grown over 330% since inception alongside the $8 billion in external business development AbbVie has deployed over the past two years.
Thirty analysts cover ABBV, with 15 Buys and 8 Outperforms against 9 Holds and zero Sells; the mean target of $249 implies 24% upside from current levels, a gap that has been widening since the stock pulled back roughly 18% from its 52-week high while full-year EPS guidance moved higher, not lower.
The $110 spread between the $184 low target and the $294 high target reveals a genuine debate worth unpacking: the $184 camp is effectively pricing in another Humira-scale commercial disruption, while the $294 end is crediting AbbVie for the full optionality of neuroscience and oncology pipeline assets, including a Parkinson’s franchise management believes can reach $5 billion in peak sales, on top of an immunology franchise already beating its own long-term benchmarks.
Trading at roughly 14x the consensus 2026 EPS estimate of approximately $14, AbbVie stock appears undervalued for a company posting the strongest earnings recovery in its post-Humira history, with normalized EPS set to grow over 40% in 2026 while the forward multiple sits well below the 18x to 20x range that large-cap pharma compounders with comparable growth profiles have historically commanded.
J&J’s recently FDA-approved oral psoriasis pill Icotyde — carrying analyst estimates of $8 billion in peak annual sales across psoriasis, ulcerative colitis, psoriatic arthritis, and Crohn’s disease — represents the sharpest near-term competitive risk to Skyrizi, given the structural preference many patients have for a once-daily oral over a biologic injection, though AbbVie’s IBD frontline capture rate of roughly 75% for Skyrizi held stable after the entry of the prior IL-23 competitor TREMFYA.
Q1 2026 earnings on April 29 will test whether AbbVie’s full-year guidance for $67 billion in revenue and adjusted EPS of $14.37 to $14.57 holds against aesthetics headwinds, Imbruvica IRA pricing pressure, and any early Icotyde market share data: watch for Skyrizi and Rinvoq combined quarterly performance relative to the roughly $7.7 billion quarterly run rate implied by full-year guidance.
What Does the Valuation Model Say?
At roughly 14x consensus 2026 EPS and approximately 7.6x consensus 2026 free cash flow of around $26 billion, AbbVie is priced as though the Humira cliff is still happening rather than already cleared, even as the ex-Humira platform delivered reported growth of 14.5% in Q4 2025.
Skyrizi and Rinvoq are on pace to generate more combined revenue in 2026 than Humira ever produced at its peak, with free cash flow set to surpass $18 billion for the first time and 30-plus business development deals executed over the past two years.
ABBV appears undervalued, trading at a ~14x forward P/E while guiding normalized EPS to grow over 40% year-over-year in 2026 — a multiple that implies the Street is still applying peak-LOE risk to a portfolio where the peak LOE is now four years in the rearview.
The central tension for AbbVie stock is not whether Skyrizi and Rinvoq can grow — they are growing at 20%-plus on a $26 billion combined base — but whether competitive pressure from oral mechanisms like Icotyde compresses the franchise’s terminal growth rate before the emerging neuroscience and oncology pipelines are large enough to absorb the deceleration.
Bull Case
- Skyrizi and Rinvoq combined 2026 guidance of over $31 billion already exceeds 2027 targets, with management projecting robust growth into the 2030s on a franchise that added more than $8 billion in annual revenue in a single year while holding IBD frontline market share above 75%
- Subcutaneous induction data for Skyrizi in Crohn’s disease showed 60% endoscopic response and 70% clinical remission in bio-naive patients, both approximately 45 percentage points above placebo — results that exceed the IV induction data and support a stronger label update for 2027
- Tavapadon oral Parkinson’s therapy on track for U.S. approval in Q3 2026, with AbbVie’s full Parkinson’s franchise including Vyalev and Duopa targeting peak sales in excess of $5 billion — a figure management noted is not yet reflected in Street models
- Free cash flow guided to approximately $18.5 billion in 2026 (around 39% FCF margin), with $8 billion deployed in external innovation over two years, including platforms in in-vivo CAR-T, bispecific antibodies, and the ABBV-295 amylin analog for obesity, which showed roughly 10% weight loss at 12 weeks in a suboptimal study population
- Mean analyst target of $249 carries no Sell-side Sell ratings among 30 analysts, a consensus configuration that has historically preceded re-rating events as EPS recoveries compound into a second year
Bear Case
- J&J’s Icotyde oral IL-23 inhibitor carries $8 billion in peak annual sales estimates across multiple indications, with oral convenience representing a structural competitive dynamic that injectable biologics have historically ceded share to over time
- Humira revenue guided to $2.9 billion in 2026 and declining further as exclusive biosimilar contracts expand, while Imbruvica faces both IRA pricing headwinds and ongoing competitive erosion in chronic lymphocytic leukemia, together creating a structural multi-billion-dollar annual drag partially offset by emerging assets
- TrenibotE aesthetics launch delayed into 2027 on manufacturing grounds, removing a market-stimulus catalyst for a segment where global aesthetics revenue was guided flat at approximately $5 billion in 2026 amid continuing macroeconomic headwinds in dermal fillers
- AbbVie’s Q1 2026 IPR&D charge of $744 million reduced adjusted EPS guidance to $13.96-$14.16, leaving limited cushion if additional pipeline write-downs occur or if Icotyde commercial uptake is faster than current analyst assumptions embed
- The FDA’s Botox selection for Medicare price negotiation in 2028 — covering roughly 30% of total Botox volume — introduces a pricing overhang on one of AbbVie’s highest-margin product lines, even as management contests the selection on statutory exemption grounds for plasma-derived biologics
Should You Invest in AbbVie Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up ABBV stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track AbbVie Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze ABBV stock on TIKR for Free →
